Publications by authors named "Michael Serbin"

Claim this Profile
L
Longitudinal Treatment Patterns of Chorea in North American Patients with Huntington's Disease: Data from Enroll-HD.
Erin Furr Stimming, Daniel O Claassen, Ginny P Sen, Olga Klepitskaya, Michael Serbin

Neurol Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Longitudinal Treatment Patterns of Chorea in North American Patients with Huntington's Disease: Data from Enroll-HD.
Erin Furr Stimming, Daniel O Claassen, Ginny P Sen, Olga Klepitskaya, Michael Serbin

Neurol Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of diagnosing provider type on longitudinal care for patients with newly diagnosed Huntington's disease.
Hyunwoo Kim, Michael Serbin, Ryan Hansen, Kyueun Lee, Dietrich Haubenberger

J Med Econ· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients' Preferences for Adjunctive Parkinson's Disease Treatments: A Discrete-Choice Experiment.
Michael Serbin, Connie Marras, Carol Mansfield, Colton Leach, Charles Yonan

Patient Prefer Adherence· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world RE-KINECT study.
Caroline M Tanner, Stanley N Caroff, Andrew J Cutler, William R Lenderking, Huda Shalhoub, Michael Serbin

J Patient Rep Outcomes· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Reply to Xue W, Ribalov R, Zhou Z-Y, et al. Re: Ganz ML, Chavan A, Dhanda R, et al. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia. J Med Econ. 2021;24(1):103-113.
Michael Serbin, Charles Yonan, Michael L Ganz

J Med Econ· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia.
Michael L Ganz, Ameya Chavan, Rahul Dhanda, Michael Serbin, Charles Yonan

J Med Econ· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa.
Ryan N Hansen, Kangho Suh, Michael Serbin, Chuck Yonan, Sean D Sullivan

J Med Econ· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
Szilárd Kiss, Joanna Campbell, Arghavan Almony, Vanessa Shih, Michael Serbin

Ophthalmology· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing Health Care Burden in Glaucoma Patients with and Without Physical or Mental Comorbidities.
Michael Serbin, Beth Devine, Joanna Campbell, Anirban Basu

J Manag Care Spec Pharm· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia.
Saurabh Aggarwal, Michael Serbin, Chuck Yonan

J Comp Eff Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis.
Michael A Serbin, Gregory F Guzauskas, David L Veenstra

J Manag Care Spec Pharm· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis